Abstract
To investigate the theoretical model of the three-dimensional structure of multidrug resistance protein 1(P-glycoprotein, expressed by MDR1 gene of E. histolytica) and its molecular docking with anti-amoebic agents. The theoretical model of multidrug resistance protein 1(P-glyoprotein, expressed by MDR1 gene of E. histolytica) was predicted by homology modeling on the structure of the 3G61. Docking studies were performed to investigate the interaction of p-glycoprotein with antiamoebic gents. MRPEH1F is significant model for p-glycoprotein and have total of 114 amino acid residues. The model is well supported by cross validation data generated after analyzing criss-cross residues, local geometry check as well as ramachandran plot. Molecular docking of MRPEH1F revealed that all the test molecules have strong binding affinity along with significant interactions. Henceforth, none of the molecules will probably be effective for the multidrug resistant strains of E. histolytica.
Keywords: 2-Pyrazolines, Entamoeba histolytica, Homology modeling, MDR1 gene, Molecular docking.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Homology Modeling of MDR1 Gene MDR1_ENTHI of E. histolytica & its Molecular Docking with Anti-Entamoeba Histolytica Agents
Volume: 15 Issue: 11
Author(s): Rajeev K. Singla
Affiliation:
Keywords: 2-Pyrazolines, Entamoeba histolytica, Homology modeling, MDR1 gene, Molecular docking.
Abstract: To investigate the theoretical model of the three-dimensional structure of multidrug resistance protein 1(P-glycoprotein, expressed by MDR1 gene of E. histolytica) and its molecular docking with anti-amoebic agents. The theoretical model of multidrug resistance protein 1(P-glyoprotein, expressed by MDR1 gene of E. histolytica) was predicted by homology modeling on the structure of the 3G61. Docking studies were performed to investigate the interaction of p-glycoprotein with antiamoebic gents. MRPEH1F is significant model for p-glycoprotein and have total of 114 amino acid residues. The model is well supported by cross validation data generated after analyzing criss-cross residues, local geometry check as well as ramachandran plot. Molecular docking of MRPEH1F revealed that all the test molecules have strong binding affinity along with significant interactions. Henceforth, none of the molecules will probably be effective for the multidrug resistant strains of E. histolytica.
Export Options
About this article
Cite this article as:
Singla K. Rajeev, Homology Modeling of MDR1 Gene MDR1_ENTHI of E. histolytica & its Molecular Docking with Anti-Entamoeba Histolytica Agents, Current Topics in Medicinal Chemistry 2015; 15 (11) . https://dx.doi.org/10.2174/1568026615666150317222927
DOI https://dx.doi.org/10.2174/1568026615666150317222927 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Proteinase-Activated Receptor-2: Physiological and Pathophysiological Roles
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Role of Angiogenesis as a Prognostic Factor of Breast Cancer: Recent Review
Current Women`s Health Reviews Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer
Current Drug Targets Bone Seeking Radiopharmaceuticals for Palliation of Pain in Cancer Patients with Osseous Metastases
Anti-Cancer Agents in Medicinal Chemistry Tackling Cardiovascular Risk: New Evidence from Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Transport of Bupropion and its Metabolites by the Model CHO and HEK293 Cell Lines
Drug Metabolism Letters A Novel Trypsin and α-Chymotrypsin Inhibitor from Maclura pomifera Seeds
Letters in Drug Design & Discovery Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Inhibiting the “Undruggable” RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products
Current Medicinal Chemistry Medicinal Plant <i>Centipeda Minima</i>: A Resource of Bioactive Compounds
Mini-Reviews in Medicinal Chemistry A Three-gene-based Type 1 Diabetes Diagnostic Signature
Current Pharmaceutical Design Role of T Lymphocytes in the Development of Rheumatoid Arthritis. Implications for Treatment
Current Pharmaceutical Design Metalloproteinases Suppression Driven by the Curcumin Analog DM-1 Modulates Invasion in BRAF-Resistant Melanomas
Anti-Cancer Agents in Medicinal Chemistry Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Bioavailability Enhancement of Coenzyme Q10: An Extensive Review of Patents
Recent Patents on Drug Delivery & Formulation Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Recent Developments in Nanomedicines for Management of Various Health Issues Via Metabolism and Physico-Chemical Properties
Current Drug Metabolism Synthesis and Biological Evaluation of Estradiol-Core Derivatives Bearing a Fused γ-Lactone as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1
Current Enzyme Inhibition